What is XAIR's current stock price?

XAIR (Beyond Air, Inc.) is currently trading at $0.41 with a market cap of $2.1M.

What sector is Beyond Air, Inc. in?

Beyond Air, Inc. (XAIR) operates in the Healthcare sector, specifically in the Medical - Devices industry.

Is XAIR a good stock to buy?

Analysts have a Buy consensus on XAIR with a price target of $1.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

XAIR Beyond Air, Inc.

Healthcare

$0.41+0.00%OpenMarket Cap: $2.1M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.43

P/S

0.29

EV/EBITDA

-0.55

DCF Value

$-2.11

FCF Yield

-1089.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

1.8%

Operating Margin

-419.5%

Net Margin

-447.7%

ROE

-279.6%

ROA

-84.3%

ROIC

-90.3%

Financials

View All

Period	Revenue	Net Income	EPS
Q3 null	$2.2M	$-7.3M	$—
Q2 null	$1.8M	$-7.9M	$—
Q1 null	$1.8M	$-7.7M	$—
Q4 null	$1.2M	$-8.0M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$1.00

Target (Median)

$1.00

Target Range

$1.00 - $1.00

1 Strong Buy2 Buy1 Hold0 Sell0 Strong Sell

D. Boral CapitalBuy

2026-03-27

D. Boral CapitalBuy

2026-01-21

D. Boral CapitalBuy

2025-11-11

D. Boral CapitalBuy

2025-08-21

Trading Activity

Insider Trades

View All

MOORHEAD DANIEL Jofficer: Chief Financial Officer

SellTue Jan 06

MOORHEAD DANIEL Jofficer

SellTue Jan 06

Lee Yooridirector

SellMon Nov 24

Lee Yooridirector

SellMon Nov 24

Lee Yooridirector

SellMon Nov 24

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

Exchange

—

Beta

0.30

Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

Peers